Skip to main navigation
Skip to search
Skip to main content
Sort by
Immunology and Microbiology
Visceral Leishmaniasis
100%
Human immunodeficiency virus
64%
Cutaneous Leishmaniasis
63%
Infection
51%
Infectious Disease
46%
Leishmaniasis
41%
Leishmania
39%
Prevalence
22%
Coinfection
21%
Ribonucleic Acid
15%
Blood Plasma
15%
COVID-19
14%
Schistosomiasis
13%
Phlebotominae
13%
Viral Disease
12%
Parasite
12%
Antigen
11%
Monkeypox Virus
10%
Sodium Stibogluconate
10%
Ebola Virus
10%
Malaria
10%
Severe Acute Respiratory Syndrome Coronavirus 2
9%
Epitope
9%
Leishmania tropica
9%
Antigen-Antibody Interaction
8%
Hepatitis C Virus
8%
Leishmania donovani
8%
Real Time Polymerase Chain Reaction
7%
ELISA
7%
CD4 Lymphocyte Count
7%
Zika virus
7%
T Cell
7%
Susceptibility
7%
Hepatitis C
6%
Immunoassay
6%
Praziquantel
6%
Polymerase Chain Reaction
6%
Arm
6%
Kinetoplast
6%
Coronavirinae
6%
Human Leukocyte Antigen
6%
Chikungunya virus
6%
Antibiotic Resistance
5%
Cohort Effect
5%
Escherichia coli
5%
Phlebotomus
5%
Schistosoma
5%
Dengue Fever
5%
Serotype
5%
Medicine and Dentistry
Ethiopia
97%
Visceral Leishmaniasis
42%
Cutaneous Leishmaniasis
42%
Human immunodeficiency virus
37%
Diseases
32%
Treatment Outcome
18%
Cross Sectional Study
18%
Clinical Trial
17%
Schistosomiasis
16%
Virus Infection
16%
Tuberculosis
16%
Neglected Tropical Diseases
16%
Malaria
16%
Mixed Infection
15%
Ebolavirus
14%
Antiretroviral Therapy
13%
Infection
13%
Leishmaniasis
11%
Sodium Stibogluconate
10%
Antibiotics
9%
Health Care Personnel
9%
Patient Referral
9%
COVID-19
9%
Monkeypox
9%
African Trypanosomiasis
9%
Retrospective Cohort Study
8%
Tuberculosis Treatment
7%
Leishmania
7%
Public Health
7%
Prevalence
7%
Paromomycin
6%
Adolescence
6%
Malnutrition
6%
Retrospective Study
6%
Amphotericin B Lipid Complex
6%
Monkeypox Virus
6%
Praziquantel
6%
Drug Administration
6%
Hansen's disease
6%
Scabies
6%
Podoconiosis
6%
Antibody Response
6%
Post-Exposure Prophylaxis
6%
Low and Middle Income Countries
6%
Pathogen
5%
Bacterial Infection
5%
Rabies
5%
Health Care
5%
Emergency Department
5%
Rapid Test
5%
Miltefosine
5%
Nursing and Health Professions
Skin Leishmaniasis
21%
Visceral Leishmaniasis
13%
Treatment Outcome
13%
Diseases
11%
Malaria
10%
Cross-Sectional Study
9%
COVID-19
9%
Infection
9%
Human immunodeficiency virus
8%
Health Care Facility
7%
Virus Infection
6%
Systematic Review
6%
Patient Referral
6%
Meta Analysis
6%
Scabies
6%
Confidence Interval
6%
Cohort Analysis
5%
Mixed Infection
5%
Treatment Failure
5%